Novo Nordisk And Gilead Expand NASH Alliance
Duo Exploring Combo Approaches To Treat Cirrhosis
Novo Nordisk and Gilead Sciences have expanded their clinical collaboration in non-alcoholic steatohepatitis following positive data from a proof-of-concept trial.
You may also be interested in...
Tempest goes public via a reverse merger with Millendo. Takeda inks its ninth deal of 2021, a discovery pact with BridGene around its chemoproteomics technology.
With still no approved therapy for non-alcoholic steatohepatitis, Intercept, Madrigal, Inventiva and others used the liver meeting to build the cases for their NASH candidates.
Russian sovereign wealth fund and Sputnik V vaccine producer RDIF has teamed up with the country’s biggest bank to fund ‘home-grown’ tech and science-intensive start-ups.